Can a diabetes drug also protect the heart? new study tests liraglutide

NCT ID NCT04866667

Completed Disease control Sponsor: Zhejiang Provincial People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study screened 316 people with type 2 diabetes who were at high risk for heart disease. Researchers tested whether adding the drug liraglutide to standard care could reduce new heart problems like heart attacks, strokes, and hospitalizations. The goal was to see if this approach could better control blood sugar, cholesterol, and blood pressure while preventing cardiovascular events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: liraglutide (a GLP-1 receptor agonist drug)
What this could lead to: If successful, this could show that liraglutide helps prevent heart attacks, strokes, and other cardiovascular problems in people with type 2 diabetes.
What could go wrong: This is a completed study with 316 participants, but results are not yet widely reported. The benefit may be modest and not apply to all diabetes patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arteriosclerosis disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARTERIOSCLEROTIC CARDIOVASCULAR DISEASE LIRAGLUTIDE TYPE 2 DIABETES MELLITUS

Contacts and locations

Locations

Zhejiang provincial people's hospital

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.